0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Use of Autologous Serum in the Treatment of Ocular Surface Disorders

Bennie H. Jeng, MD
Arch Ophthalmol. 2011;129(12):1610-1612. doi:10.1001/archophthalmol.2011.336.
Text Size: A A A
Published online

Extract

The use of autologous serum for treating ocular surface disorder has a long history that dates back at least to the 1970s when autologous serum was used via a mobile ocular perfusion pump to treat ocular alkali burns.1 Subsequently, a report2 in the rheumatologic literature appeared in 1984 discussing the use of autologous serum as a tear substitute. Although probably used more often than it was publicized to be, the use of autologous serum for the treatment of ocular surface disorder did not appear to garner widespread interest until the late 1990s (Figure). Since that time, this treatment modality has become increasingly popular, and the indications for its use have expanded rapidly. However, despite the reported successes of the use of this product, there are clinical and nonclinical concerns about this therapy that must also be addressed.

Figures in this Article

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure. The number of clinical studies (including case reports) published on the use of autologous serum for ocular surface disorder from January 1975 through December 2010. The search was conducted using PubMed with the key words “autologous serum eye.” All resultant studies were reviewed, and only clinical reports pertaining to the use of autologous serum for the treatment of various types of ocular surface disorders were included.

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();